Cash-Poor, Nuvelo to Scrap All of Variagenics PGx Assets; Hyseq s Array Unit Also for Sale | GenomeWeb

In a strategic shift that illustrates its relentlessly shaky cash position, Nuvelo said it will put on the block all of the pharmacogenomics assets that belonged to Variagenics, as well as the microarray business cultivated by Hyseq, its former corporate incarnation, SNPtech Reporter has learned.

Reporting his company’s second-quarter earnings last week, CEO Ted Love said Nuvelo will “monetize” non-core assets acquired from Variagenics last November.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.